Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
Moku P, Shepherd L, Ali SM, Leitzel K, Parulekar WR, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon K, Drabick J, Cream L, Halstead ES, Umstead TM, Mckeone D, Polimera H, Maddukuri A, Ali A, Nagabhairu V, Poulose J, Pancholy N, Spiegel H, Chen BE, Lipton A. Moku P, et al. Among authors: parulekar wr. Cancer. 2020 Nov 15;126(22):4859-4866. doi: 10.1002/cncr.33149. Epub 2020 Sep 10. Cancer. 2020. PMID: 32910476 Free article.
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI; National Cancer Institute of Canada Clinical Trials Group. Parulekar WR, et al. J Clin Oncol. 2005 Sep 1;23(25):6002-8. doi: 10.1200/JCO.2005.07.096. J Clin Oncol. 2005. PMID: 16135468
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. da Cunha Santos G, et al. Cancer. 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7. Cancer. 2010. PMID: 20824720 Free article. Clinical Trial.
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Goodwin PJ, et al. Among authors: parulekar wr. Breast Cancer Res Treat. 2011 Feb;126(1):215-20. doi: 10.1007/s10549-010-1224-1. Epub 2010 Oct 26. Breast Cancer Res Treat. 2011. PMID: 20976543 Review.
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P. Mason MD, et al. Among authors: parulekar wr. J Clin Oncol. 2015 Jul 1;33(19):2143-50. doi: 10.1200/JCO.2014.57.7510. Epub 2015 Feb 17. J Clin Oncol. 2015. PMID: 25691677 Free PMC article. Clinical Trial.
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.
Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Goodwin PJ, et al. Among authors: parulekar wr. J Natl Cancer Inst. 2015 Mar 4;107(3):djv006. doi: 10.1093/jnci/djv006. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25740979 Free PMC article. Clinical Trial.
105 results